Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01 plus Tislelizumab in Advanced Solid Tumors and Lymphomas
NCT05833984Phase 2Unknown
- Sponsor
- ImmuneOnco
- Start
- May 2022
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
A Phase 2 trial of timdarpacept in solid tumor, classic Hodgkin lymphoma (cHL), sponsored by ImmuneOnco. Status: unknown.
02
Drugs
timdarpacept
03
Conditions
solid tumorclassic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05833984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833984.